Is Dacomitinib an imported drug?

Dacomitinib is a second-generation tyrosine kinase inhibitor developed by Pfizer of the United States. It is specially used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. As an oral, selective, adenosine triphosphate (ATP)-competitive small molecule inhibitor, it exerts a powerful anti-tumor effect by irreversibly binding to tyrosine kinases of the EGFR family.

It is worth mentioning that dacomitinib not only has significant efficacy onEGFR (HER1), but also inhibits related proteins such as HER2 and HER4. This pan-HER inhibitory property allows it to also show certain efficacy in the treatment of patients with HER2 and EGFR20ins. In addition, the irreversible binding properties of dacomitinib theoretically provide longer-lasting and more stable inhibitory effects compared with first-generation tyrosine kinase inhibitors.

In terms of medication, the recommended dose of dacomitinib is45 mg, taken orally once a day, and the dose can be adjusted according to the patient's tolerance. However, like other drugs, dacomitinib may also cause some adverse reactions, such as diarrhea, rash, paronychia, etc. Therefore, it is necessary to pay close attention to the patient's reaction during use and adjust the treatment plan in a timely manner.

In China, the original drug dacomitinib has been launched and enjoys medical insurance reimbursement. Please consult the medical insurance department for specific reimbursement ratios. The price of 30 tablets of 15mg only costs more than 1,000 yuan after medical insurance reimbursement. In addition, generic drugs of this drug are also available in Laos. The price of 30 tablets of 45mg is about 1,500 yuan per box from Element Pharmaceuticals and about 1,200 yuan from Lucius Pharmaceuticals. If you have questions about the price of dacomitinib, you can consult a professional overseas medical consulting company.

In general, dacomitinib, as an imported lung cancer treatment drug, provides a new treatment option for NSCLC patients with EGFR gene mutations by virtue of its unique panHER inhibitory properties and irreversible binding mechanism. Although it is necessary to pay attention to the monitoring and management of adverse reactions during use, its efficacy in clinical practice undoubtedly brings more hope to patients.